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Abstract
Background: The purpose of this systematic review and meta-analysis of randomised controlled trials (RCTs) was to
evaluate the pain control by gabapentin or pregabalin administration versus placebo after total hip arthroplasty
(THA).
Methods: In January 2016, a systematic computer-based search was conducted in the Medline, Embase, PubMed,
CENTRAL (Cochrane Controlled Trials Register), Web of Science and Google databases. This systematic review and
meta-analysis were performed according to the PRISMA statement criteria. The primary endpoint was the
cumulative morphine consumption and visual analogue scale (VAS) scores at 24 and 48 h with rest or mobilisation.
The complications of vomiting, nausea, dizziness and pruritus were also compiled to assess the safety of
gabapentin and pregabalin. Stata 12.0 software was used for the meta-analysis. After testing for publication bias
and heterogeneity across studies, the data were aggregated for random-effects modelling when necessary.
Results: Seven studies involving 769 patients met the inclusion criteria. The meta-analysis revealed that treatment with
gabapentin or pregabalin can decrease the cumulative morphine consumption at 24 h (mean difference (MD) = −7.82;
95 % CI −0.95 to −0.52; P < 0.001) and 48 h (MD = −6.90; 95 % CI −0.95 to −0.57; P = 0.118). Gabapentin or pregabalin
produced no better outcome than placebo in terms of VAS score with rest at 24 h (SMD = 0.15; 95 % CI −0.17 to −0.48;
P = 0.360) and with rest at 48 h (SMD = 0.22; 95 % CI −0.25 to 0.69; P = 0.363). There was no statistically significant
difference between the groups with respect to the VAS score at 24 h postoperatively (SMD = 0.46; 95 % CI −0.19 to 1.
11; P = 0.164) and at 48 h postoperatively (SMD = 1.15; 95 % CI −0.58 to 2.89; P = 0.193). Gabapentin decreased the
occurrence of nausea (relative risk (RR), 0.49; 95 % CI 0.27–0.92, P = 0.025), but there was no significant difference in the
incidence of vomiting, dizziness and pruritus.
Conclusions: On the basis of the current meta-analysis, gabapentin or pregabalin can decrease the cumulative
morphine consumption and decrease the occurrence of nausea; however, further trials are needed to assess the
efficacy of pain control by gabapentin or pregabalin.
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Background
Postoperative pain after total hip arthroplasty (THA) re-
mains one of the most difficult types of pain to manage.
Resuming ambulation as soon as possible after the oper-
ation can decrease the occurrence of deep venous throm-
bosis (DVT) and the economic cost of recovery [1, 2].
Many therapeutic modalities–ranging from nonsteroidal
anti-inflammatory drugs (NSAIDs) to systemic opioids,
acetaminophen, patient-controlled opioid analgesia and
tramadol–have been used for postoperative pain manage-
ment [3–7]. However, NSAIDs increase the occurrence of
bleeding. Opioids increase the risk of nausea and vomiting
as well as respiratory depression. Patient-controlled anal-
gesia always provides inadequate analgesia for movement,
which may delay hospital discharge. Acetaminophen alone
provides pain relief, and thus, more opioids are required
for rescue analgesia [8].
Contemporary postoperative pain management is
aimed at enhancing pain relief and decreasing opioid
consumption by combining analgesic drugs and tech-
niques to reduce opioid-related complications. According
to animal studies, pregabalin may reduce hyperalgesia
related to inflammation or opioids [9, 10]. Gabapentin
and pregabalin, referred to as gabapentinoids, are struc-
tural analogues of gamma-amino butyric acid, which is
an anticonvulsant drug that possibly exerts its effects
through voltage-dependent calcium channels. Gabapen-
tin and pregabalin have similar antiallodynic and antihy-
peralgesic properties, which may be beneficial in
controlling postoperative pain after THA. Many studies
have compared gabapentin or pregabalin with placebos
in managing pain after THA. However, there are no sys-
tematic reviews that evaluate the efficacy and safety of
gabapentin or pregabalin for pain control after THA.
We therefore searched electronic databases and con-
ducted a systematic review and meta-analysis to identify
the clinical outcome and safety of gabapentin or prega-
balin in reducing pain after THA.
Methods
Search strategy
The following electronic databases were searched for
relevant academic clinical trials comparing perioperative
gabapentinoids (gabapentin and pregabalin) to a placebo
for the management of pain after THA from inception
to January 2016: Medline, Embase, PubMed, CENTRAL
Fig. 1 The flow diagram of the included studies
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(Cochrane Controlled Trials Register), Web of Science
and Google (Additional file 1). Both gabapentin and
pregabalin have antiallodynic and antihyperalgesic
properties, which may be beneficial in controlling
postoperative pain after THA. Therefore, we incorpo-
rated these two drugs in this meta-analysis. The key
words and medical subject heading (Mesh) terms in-
cluded the following: gabapentin, pregabalin, pain
control, total hip arthroplasty, total hip replacement,
THA and THR. These key words and the correspond-
ing MeSH terms were combined with the Boolean op-
erators AND and OR. Furthermore, the reference lists
of the identified literature were reviewed to identify
any initially omitted studies, and no restriction was
made on the language of the publication. Two re-
viewers independently searched the databases and fil-
tered the relevant literature. Conflicts were resolved
by the third reviewer. The full articles were screened
to determine whether the articles fit the inclusion and
exclusion criteria. Because this is a meta-analysis, no
ethics committee or institutional review board ap-
proval was required.
Inclusion criteria and study selection
The inclusion criteria were as follows: (1) randomised
controlled trials (RCTs); (2) patients who underwent a
primary THA; (3) interventions, including gabapentin or
pregabalin, versus control (placebo or nothing); and (4)
reported outcomes, including postoperative VAS pain
with rest or mobilisation at 24 and 48 h, cumulative
morphine consumption at 24 and 48 has well as the in-
cidence of pruritus, vomiting, dizziness, and nausea. The
article needed to include at least one of the outcomes
mentioned above. We excluded studies of cadavers or
artificial models. We also excluded non-RCTs, letters,
comments, editorials, practice guidelines and other stud-
ies with insufficient data.
Data abstraction and quality assessment
Duplicates were excluded using Endnote software, and
two reviewers independently screened the titles and ab-
stracts of the searched literature. Most of the articles
were excluded on the basis of the topic of the article
provided in the title or abstract, and disagreements
about whether an article should be included were
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resolved by discussion or by a senior reviewer. Postoper-
ative pain intensity was measured on a 100-point visual
analogue scale (VAS). The 10-point VAS score and nu-
merical rating scale were converted to a 100-point VAS
score according to the reference. Data in other forms
(i.e., median, interquartile range and mean ± 95 % CI)
were converted to mean ± SD according to the Cochrane
Handbook. If the data were not reported numerically,
we extracted them using the “GetData Graph Digitizer”
software from the published figures.
The following data were extracted and recorded in a
spreadsheet: (1) the author’s name, demographic data
about the number of patients in the gabapentin and con-
trol groups, the number of male patients in each group,
the dose and time to administration of gabapentin and
the anaesthesia method; (2) intraoperative and postoper-
ative analgesia; and (3) the VAS score with rest or mobil-
isation at 24 and 48 h, the incidence of pruritus,
vomiting, dizziness, sedation and nausea, and the cumu-
lative morphine consumption at 24 and 48 h. Two re-
viewers independently scanned the quality of the eligible
studies. Discrepancies were resolved by consensus after
discussion, and a third reviewer participated in the de-
bate to determine the final outcome if necessary. The
risk of bias for each RCT was evaluated using the
Cochrane Collaboration’s Risk of Bias Tool.
Statistical analysis
Continuous outcomes such as the VAS score with rest
or mobilisation at 24 and 48 h and the cumulative mor-
phine consumption at 24 h and 48 h were expressed as
the mean difference (MD) with the respective 95 % CIs.
Discontinuous outcomes (i.e., the incidence of pruritus,
vomiting, dizziness, sedation and nausea) were expressed
as the relative risk (RR) with 95 % CIs. Statistical signifi-
cance was set at P < 0.05 to summarise the findings
across the trials. Risk of bias assessment for each in-
volved article was conducted in light of the Cochrane
Handbook for Systematic Reviews of Interventions using
RevMan 5.30 software (The Cochrane Collaboration,
Oxford, United Kingdom). The meta-analysis values
were calculated by Stata, version 12.0 (Stata Corp.,






Mean difference (95 % CI)
or risk ratio (95 % CI)
Heterogeneity p-value (I2) Model
24 h cumulative consumption
Overall 5 540 <0.001 −7.82 (−0.95, −0.52) <0.001 (87.2 %) random
Gabapentin 3 300 <0.001 −2.65 (−3.67, −1.63) 0.427 (0 %) random
Pregabalin 2 240 <0.001 −19.42 (−11.72, −3.93) <0.001 (59.9 %) random
48 h cumulative consumption
Overall 5 378 0.118 −6.90 (−0.95, 0.57) <0.001 (93.7 %) random
Gabapentin 3 258 1.000 0.00 (−7.69, 7.69) <0.001 (94.5 %) random
Pregabalin 2 120 <0.001 −33.02 (−45.86, −20.19) 0.989 (0.00 %) random
VAS score with rest at 24 h
Overall 5 451 0.360 0.15 (−0.17, −0.48) 0.017 (63.7 %) random
Gabapentin 3 300 0.076 0.32 (−0.03, 0.67) 0.082 (55.3 %) random
Pregabalin 2 151 0.486 −3.05 (−11.63, 5.53) 0.193 (41.1 %) random
VAS score with rest at 48 h
Overall 3 331 0.363 0.22 (−0.25, 0.69) 0.003 (78 %) random
Gabapentin 2 258 0.049 0.41 (0.00, 0.81) 0.072 (62.1 %) random
Pregabalin 1 73 0.106 NS NS NS
VAS score with mobilization at 24 h
Overall 5 451 0.164 0.46 (−0.19, 1.11) <0.001 (91 %) random
Gabapentin 3 300 1.137 0.72 (0.23, 1.66) <0.001 (93.1 %) random
Pregabalin 2 151 0.803 −0.78 (−6.91, 5.35) 0.799 (0 %) random
VAS score with mobilization at 48 h
Overall 3 331 0.193 1.15 (−0.58, 2.89) <0.001 (97.8 %) random
Gabapentin 2 258 0.045 1.90 (0.04, 3.75) <0.001 (97.2 %) random
Pregabalin 1 73 <0.001 NS NS NS
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College Station, TX). Different gabapentin doses and
dosing times in a single study were handled as sub-
groups within the study. Statistical heterogeneity was
tested using the chi-squared test and I2 statistic. A chi-
squared test scoring I2 > 50 % was considered suggestive
of statistical heterogeneity. When there was no statis-
tical evidence of heterogeneity, a fixed effects model
was adopted; otherwise, a random effects model was
chosen. Publication bias was tested by Begg’s test and




In the initial search, we identified 312 potentially rele-
vant studies, of which 30 duplicates were removed by
Endnote software (Fig. 1). According to the inclusion
criteria, 276 studies were excluded after reading the titles
and abstracts. Finally, we included seven clinical trials
with 769 patients in the meta-analysis [11–17]. In the in-
cluded studies, one trial used gabapentin in a different
phase, and the groups were classified into preoperative
administration and postoperative administration. Thus,
the study was divided into two groups. The characteris-
tics of the included studies are shown in Table 1. The
number of patients ranged from 23 to 78. One study
[14] performed THA using general anaesthesia, and the
others performed THA by using spinal anaesthesia. In
the included studies, a total of 621 THAs were per-
formed, and the number of patients who received gaba-
pentin, pregabalin or placebo was 150, 181 and 290,
respectively. One article was published in 2008 [15]; one
was published in 2009 [13] and the others were pub-
lished from 2010 to 2015 [11, 12, 14, 16]. The partici-
pants in the five studies were mostly elderly, and the age
of the patients ranged from 58.9 to 72 years. There were
266 male patients and 355 female patients. Four studies
focused on the administration of pregabalin, and three
studies on the administration of gabapentin for pain
control after THA. The dose of pregabalin ranged from
150 to 300 mg/day preoperatively, and the dose of gaba-
pentin ranged from 600 to 1200 mg/day preoperatively.
The administration time for pregabalin and gabapentin
was 1 and 2 h before surgery. Two studies performed
Fig. 2 The detailed bias summary of each study
Fig. 3 The bias summary concluded in the above graph
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Fig. 4 Begg’s funnel plot with pseudo 95 % CI
NOTE: Weights are from random effects analysis
Overall  (I-squared = 31.4%, p = 0.188)
Clarke P/G (2009)




























Fig. 5 The forest plot of occurrence of vomiting between the two groups
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the surgical procedure using the lateral approach for
arthroplasty [15, 17], one study performed THA using
posterior surgical approach [14] and the remaining stud-
ies did not state the approach used for performing THA
[11–13, 16]. The postoperative analgesia included
patient-controlled analgesia (PCA) and morphine or cel-
ecoxib. Details are shown in Table 2. All seven RCTs in-
troduced randomisation, of which six trials were
randomised by the computer-generated block method
and one study was randomised by Randomization.com;
only one trial did not imply blinding of outcome assess-
ment. The risk of bias is shown in Figs. 2 and 3.
Results of the meta-analysis
Cumulative morphine consumption at 24 and 48 h
A total of five studies addressed the cumulative mor-
phine consumption at 24 h and 48 h in the gabapentin
or pregabalin and control groups. The results indicated
that perioperative gabapentin or pregabalin can decrease
the cumulative morphine consumption at 24 h (MD=
−7.82; 95 % CI −0.95 to −0.52; P < 0.001) and 48 h (MD=
−6.90; 95 % CI −0.95 to −0.57; P = 0.118, Table 2). Begg’s
funnel plot is approximately asymmetrical and thus
indicated that there is no publication bias between the in-
cluded studies for the cumulative morphine consumption
by 24 h (P = 0.133, Fig. 4).
Subgroup analyses were conducted to analyse the effi-
cacy of gabapentin and pregabalin for pain control after
THA. The results indicated that gabapentin can decrease
the cumulative morphine consumption at 24 h (−2.65,
(−3.67, −1.63), P < 0.001) and 48 h (0.00, (−7.69, −7.69),
P < 0.001) with a significant difference (Table 2). Prega-
balin can also decrease the cumulative morphine con-
sumption at 24 h (−19.42 (−11.72, −3.93)) and 48 h
(−33.02 (−45.86, −20.19)) with a significant difference
(Table 2).
VAS score with rest
Only five studies with 451 patients provided a VAS
score at 24 h after surgery with rest. Among these
studies, one study divided the gabapentin group into
two groups according to whether the gabapentin was
administered preoperatively or postoperatively; thus, a
total of six clinical studies were included. Our meta-
analysis revealed that gabapentin produced no better
outcome than placebo in terms of VAS scores with
NOTE: Weights are from random effects analysis
Overall  (I-squared = 0.0%, p = 0.730)
Mathiesen  (2008)
Clarke H  (2015)
Study


























Fig. 6 The forest plot of occurrence of nausea between the two groups
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rest at 24 h (SMD= 0.15; 95 % CI −0.17 to −0.48; P =
0.360, Table 2) and with rest at 48 h (SMD= 0.22; 95 % CI
−0.25 to 0.69; P = 0.363, Table 2).
VAS score with mobilisation
A total of five studies (451 patients) provided VAS
scores at 24 h with postoperative mobilisation. There
was no statistically significant difference between the
groups with respect to the VAS scores at 24 h postopera-
tively (SMD = 0.46; 95 % CI −0.19 to 1.11; P = 0.164,
Table 2). Only three studies with 331 THAs reported the
VAS score at 48 h postoperatively; our meta-analysis
found no significant difference between the two groups
(SMD = 1.15; 95 % CI −0.58 to 2.89; P = 0.193, Table 2).
Complications
Seven studies closely monitored postoperative vomiting.
Our meta-analysis identified no significant difference be-
tween the two methods in terms of postoperative vomit-
ing (RR, 0.95; 95 % CI 0.47–1.92, P = 0.895, Fig. 5), with
a low heterogeneity (I2 = 31.4 %, χ2 = 7.30). Six studies
investigated the occurrence of nausea in both methods
and found that the administration of gabapentin or preg-
abalin can increase the occurrence of nausea (RR, 0.49;
95 % CI 0.27–0.92, P = 0.025, Fig. 6). In addition to the
above complications, there was no statistically significant
difference between the incidence of dizziness and prur-
itus (RR, 0.82; 95 % CI 0.51–1.33, P = 0.429; RR, 0.89;
95%CI 0.57–1.39, P = 0.600, Figs. 7 and 8).
Discussion
To our knowledge, this is the first meta-analysis of RCTs
comparing the efficacy and safety of gabapentin or prega-
balin with placebo for the management of pain after THA.
The present meta-analysis was conducted on the basis of
seven randomised studies that found lower cumulative
morphine consumption at 24 h and 48 h postoperatively
with gabapentin or pregabalin administration than with
placebo. There was no significant difference between the
two groups with mobilisation at 24 h or 48 h. In addition,
perioperative gabapentin administration can decrease the
occurrence of nausea; however, there is no significant dif-
ference between the two groups in terms of incidence of
vomiting, dizziness and pruritus.
The results of our meta-analysis indicated that pre-
operative gabapentin or pregabalin can decrease the cu-
mulative morphine consumption at 24 h and 48 h, and
the difference is statistically significant. The management
NOTE: Weights are from random effects analysis
























Fig. 7 The forest plot of occurrence of dizziness between the two groups
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of acute pain after THA has been well studied and in-
volves multimodal analgesia, including opioids and other
adjuncts, such as dexamethasone, morphine, pregabalin
and gabapentin [12, 16, 18, 19]. The two main purposes of
balanced analgesia are to improve analgesia and reduce
the complications. A large number of trials have suggested
limited or no benefits of pregabalin or gabapentin for
acute pain and a significant reduction in pain control after
surgery [20–22]. Gabapentin was first introduced as an
antiepileptic drug in 1993 and has since been used to treat
painful neuropathies. Pregabalin was introduced as an
anticonvulsant in 2004 [23]. Compared with gabapentin,
pregabalin possesses superior oral absorption and bioavail-
ability; thus, pregabalin has attracted much interest as an
adjunct in the management of neuropathic and postopera-
tive pain.
There is no significant difference between the VAS
scores at 24 and 48 h with rest or mobilisation. However,
there is not enough data to compile for VAS scores from
operation to 24 h. Subgroup analysis indicated that neither
gabapentin nor pregabalin is superior to placebo. The pri-
mary mechanism of gabapentin action is achieved in com-
bination with the 21 subunits of presynaptic voltage-gated
calcium channels. The expression of these channels is
upregulated upon nerve injury. Furthermore, gabapentin
can decrease the hyperexcitability of secondary nocicep-
tive neurons in the dorsal horn. The relevant VAS score in
the included studies were reported only for 24 and 48 h,
and the long-term pain control effect is unknown. Hence,
studies on the long-term effect of gabapentin or pregaba-
lin for pain control after THA are needed. Yao et al. [24]
conducted a meta-analysis to compare preoperative prega-
balin for pain control in gynaecological surgery and found
that it has analgesic and opioid-sparing effects and does
not increase the frequency of adverse effects. Eipe et al.
[25] conducted a meta-analysis to compare the effects of
pregabalin for acute pain and concluded that the analgesic
effectiveness is largely restricted to surgical procedures.
Another reason may be that all the studies involved ad-
ministration of postoperative analgesia in the form of
patient-controlled analgesia. This method achieves better
pain control; thus, additional gabapentin or pregabalin are
not needed to achieve better pain control after THA.
Gabapentin or pregabalin can decrease the occurrence
of nausea without increasing the complications of vomit-
ing, pruritus and dizziness with a low heterogeneity.
Morphine-related complications, including pruritus and
dizziness, especially dizziness, may prolong the length of
NOTE: Weights are from random effects analysis
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Fig. 8 The forest plot of occurrence of pruritus between the two groups
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hospital stay and thus increase the economic burden.
Since gabapentin or pregabalin can decrease the cumula-
tive morphine consumption, this is one of the reasons
for the decrease in the incidence of nausea. Another
point of clinical significance is that gabapentin can suc-
cessfully reduce opioid consumption and thus can lead
to more stable haemodynamics and reduced respiratory
depression. Since the sample size is limited, the other
complications did not reach statistical significance.
Therefore, more high-level RCTs are needed to fur-
ther identify the complications of gabapentin or preg-
abalin for THA. In this meta-analysis, patient-
reported outcomes were not specifically assessed. Two
studies reported the Western Ontario and McMaster
university Osteoarthritis Index (WOMAC) score; how-
ever, this score did not show a significant difference
between pregabalin or gabapentin versus placebo in
the two studies [11, 12].
There were several limitations in this meta-analysis:
(1) only seven RCTs were included, and sample sizes of
the included studies were relatively small, which might
have affected the precision of the effect size estimations.;
(2) we only included studies with immediate follow-up
at 24 and 48 h postoperatively; (3) the dose and time of
gabapentin or pregabalin differed between the studies,
which will affect the precision of the results; (4) the mul-
tiple analgesia approaches are different from each other,
and consistent multiple analgesia approaches are needed
to identify the most effective pain control method; and
(5) even though the Begg’s test provides evidence of fun-
nel plot symmetry indicating that there is no publication
bias, we cannot completely exclude publication bias be-
cause the number of the studies included was limited.
Conclusions
In conclusion, although the number of studies and sam-
ples in each paper is limited, this is the first meta-
analysis that compares the use of gabapentin or pregaba-
lin with a placebo for the management of pain after
THA. Our meta-analysis revealed that gabapentin has an
analgesic- and opioid-sparing effect in acute postopera-
tive pain management without increasing the incidence
of nausea. Because the sample size and number of in-
cluded studies is limited, a multiple central randomised
controlled trial is needed to identify the effects and opti-
mal dose of gabapentin for reducing pain after THA.
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